LeMaitre Vascular (NASDAQ:LMAT) Rating Reiterated by Barrington Research

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “outperform” rating reaffirmed by Barrington Research in a note issued to investors on Friday, Benzinga reports. They presently have a $92.00 price objective on the medical instruments supplier’s stock. Barrington Research’s target price points to a potential upside of 1.94% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the company. Roth Mkm reiterated a “buy” rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Lake Street Capital started coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Finally, Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $94.40.

LeMaitre Vascular Trading Up 0.1 %

LMAT traded up $0.07 during trading on Friday, hitting $90.25. The company’s stock had a trading volume of 39,422 shares, compared to its average volume of 123,707. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of 59.77, a P/E/G ratio of 2.28 and a beta of 0.88. The business’s fifty day simple moving average is $86.76 and its 200 day simple moving average is $77.84. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.37 EPS. As a group, equities research analysts forecast that LeMaitre Vascular will post 1.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO George W. Lemaitre sold 12,976 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $86.07, for a total value of $1,116,844.32. Following the completion of the transaction, the chief executive officer now owns 1,985,358 shares of the company’s stock, valued at $170,879,763.06. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The disclosure for this sale can be found here. Insiders sold a total of 43,251 shares of company stock valued at $3,714,994 over the last quarter. 10.79% of the stock is owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. YHB Investment Advisors Inc. purchased a new stake in shares of LeMaitre Vascular during the first quarter worth $36,000. GAMMA Investing LLC increased its holdings in LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares during the period. West Oak Capital LLC acquired a new stake in LeMaitre Vascular in the 2nd quarter valued at about $58,000. nVerses Capital LLC boosted its stake in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 200 shares during the period. Finally, Van ECK Associates Corp purchased a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $75,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.